Haemonetics Corp
Veridion Score
Composite trend over time
Why is HAE moving today?
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for HAE.
HAE insider activity
Haemonetics Corp
No multi-insider buying cluster in the last 90 days
Net selling: -$995K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-08 | 2026-06-05 | Maunsell Farris Maryanne | Insider | sell | $71.28 | 259 | 6,242 | $18K | SEC Form 4 |
| 2026-06-08 | 2026-06-05 | Miller Laurie A. | Insider | sell | $71.28 | 313 | 40,987 | $22K | SEC Form 4 |
| 2026-05-19 | 2026-05-15 | Chan Frank | Insider | sell | $56.29 | 546 | 5,401 | $31K | SEC Form 4 |
| 2026-05-19 | 2026-05-15 | Maunsell Farris Maryanne | Insider | sell | $56.29 | 197 | 4,281 | $11K | SEC Form 4 |
| 2026-05-19 | 2026-05-15 | Galvin Roy | Insider | sell | $56.29 | 879 | 12,347 | $49K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 8 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moHAE contract awards, year to date.
Public federal awards linked to this ticker.
HAE lobbying filings, year to date.
Registered lobbying filings matched to Haemonetics Corp.